BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 9, 2026
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Ibrutinib could be repurposed to treat glioblastoma

June 13, 2018
By John Fox

Ibrutinib could be repurposed to treat glioblastoma

June 13, 2018
By John Fox
HONG KONG – Preclinical data from a Sino-US study suggest that a tyrosine kinase inhibitor originally developed to treat lymphoma and leukemia, Imbruvica (ibrutinib, Abbvie Inc./Johnson & Johnson), could also target glioma stem cells (GSCs), effectively controlling glioblastoma growth.
Read More

Researchers identify LIMA1 as new cholesterol absorption target

June 12, 2018
By John Fox

A Chinese study has for the first time identified a key protein, known as LIMA1, which was shown to regulate intestinal cholesterol absorption in both mouse models and in humans.


Read More

Researchers identify LIMA1 as new cholesterol absorption target

June 12, 2018
By John Fox
A Chinese study has for the first time identified a key protein, known as LIMA1, which was shown to regulate intestinal cholesterol absorption in both mouse models and in humans.
Read More

Ibrutinib could be repurposed to treat glioblastoma

June 7, 2018
By John Fox
HONG KONG – Preclinical data from a Sino-US study suggest that a tyrosine kinase inhibitor originally developed to treat lymphoma and leukemia, Imbruvica (ibrutinib, Abbvie Inc./Johnson & Johnson), could also target glioma stem cells (GSCs), effectively controlling glioblastoma growth.
Read More

Isomer discovery could yield countless new drugs

June 6, 2018
By John Fox
Australian scientists have found a new way to make molecular isomers, opening up the possibility of a new area of chemistry and the development of countless new drugs and other useful new materials.
Read More

Isomer discovery could yield countless new drugs

May 30, 2018
By John Fox
Australian scientists have found a new way to make molecular isomers, opening up the possibility of a new area of chemistry and the development of countless new drugs and other useful new materials.
Read More

New malarial gene findings could aid drug development

May 16, 2018
By John Fox
HONG KONG – An international study led by the University of South Florida (USF) has revealed important new information regarding the critical genes of the deadly malarial parasite, Plasmodium falciparum, which could help investigators prioritize targets for future development of newer, more effective antimalarial drugs.
Read More

New malarial gene findings could aid drug development

May 14, 2018
By John Fox
HONG KONG – An international study led by the University of South Florida (USF) has revealed important new information regarding the critical genes of the deadly malarial parasite, Plasmodium falciparum, which could help investigators prioritize targets for future development of newer, more effective antimalarial drugs.
Read More

Vitamin A derivative selectively kills liver cancer stem cells

May 8, 2018
By John Fox
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 8, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • CAR T cell attacking cancer cells

    Development and characterization of anti-CD19 in vivo CAR T therapy

    BioWorld Science
    Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
  • Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

    BioWorld Science
    The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing